• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Mechanism of C-reactive protein on proliferation of multiple myeloma U266 cells].

作者信息

Yang Yi-Rong, Huang Ling-Juan, Ma Yan-Ping, Lu Yu-Jin, Yang Lin-Hua, Zhou Yong-An

机构信息

Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1242-5.

PMID:19840459
Abstract

This study was purposed to investigate the mechanism of C-reactive protein (CRP) on proliferation of U266 cells. The human multiple myeloma cell line U266 was incubated with human CRP (0, 5, 10, 20 mg/L) for 24 hours, then the proliferation level of U266 cells was detected by using blood analyser. The mRNA expressions of survivin and HSP90alpha were examined by RT-PCR. The results showed that the proliferation ratio was increased, as compared with the control group (p<0.05); furthermore, the mRNA levels of survivin and HSP90alpha were up-regulated in proportion to the increased CRP concentrations. There was significant correlation between expression of survivin and HSP90alpha (r=0.737, p<0.0001) in incubated cells. It is concluded that CRP can stimulate the proliferation of MM cells directly by up-regulating the expression of survivin and HSP90alpha in MM cells. CRP can be regarded as a potential target for MM treatment.

摘要

相似文献

1
[Mechanism of C-reactive protein on proliferation of multiple myeloma U266 cells].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1242-5.
2
[MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].[MS-275,一种组蛋白去乙酰化酶抑制剂,可诱导人骨髓瘤细胞系U266凋亡并改变生存素基因表达]
Ai Zheng. 2009 May;28(5):466-71.
3
[Glycyrrhetinic acid induces apoptosis and alters survivin gene expression in human myeloma cell line U266].甘草次酸诱导人骨髓瘤细胞系U266凋亡并改变生存素基因表达
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):652-5.
4
[Correlation of HSP90 mRNA expression with migration ability of human multiple myeloma cells].[热休克蛋白90(HSP90)mRNA表达与人多发性骨髓瘤细胞迁移能力的相关性]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Apr;18(2):372-5.
5
[Rosiglitazone and all-trans retinoic acid inhibit human myeloma cell proliferation via apoptosis signaling pathway modulation].罗格列酮和全反式维甲酸通过调节凋亡信号通路抑制人骨髓瘤细胞增殖
Zhonghua Xue Ye Xue Za Zhi. 2009 Apr;30(4):242-6.
6
[HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].[热休克蛋白90抑制剂17-烯丙基氨基-17-去甲氧基格尔德霉素通过下调Wnt/β-连环蛋白信号通路抑制多发性骨髓瘤细胞增殖]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):117-21. doi: 10.7534/j.issn.1009-2137.2016.01.023.
7
[Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line].姜黄素对人多发性骨髓瘤细胞系中生存素、Bcl-2和Bax表达的影响
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):762-6.
8
The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells.Rho 同源物 C/Rho 相关卷曲螺旋蛋白激酶(Rho/ROCK)信号通路对人骨髓瘤细胞增殖和凋亡的影响。
Med Sci Monit. 2019 Oct 10;25:7605-7616. doi: 10.12659/MSM.915998.
9
[Multiple myeloma cell line U266 apoptosis induced by velcade].硼替佐米诱导多发性骨髓瘤细胞系U266凋亡
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Aug;14(4):696-9.
10
[Effects of histone deacetylase inhibitor MS-275 on expression of survivin and NF-kappaB in the human myeloma cell line U266 cells].[组蛋白去乙酰化酶抑制剂MS-275对人骨髓瘤细胞系U266细胞中生存素及核因子-κB表达的影响]
Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):250-3.

引用本文的文献

1
C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms.C反应蛋白(CRP)促进胰腺神经内分泌肿瘤的恶性特性。
Endocr Connect. 2019 Jul;8(7):1007-1019. doi: 10.1530/EC-19-0132.